Anrikefon
DrugAnrikefon is a novel peripherally KOR agonist independently developed in China. In this study, anrikefon will be administered intravenously at a dose of 1 μg/kg, 15 minutes before the end of surgery.
NCT Number: NCT07269106
The goal of this clinical trial is to learn if Anrikefon works as well as nalbuphine to control postoperative pain in adults undergoing ophthalmic surgery under general anesthesia. It will also learn about the safety and recovery outcomes of using Anrikefon.
The main questions it aims to answer are:
* Does Anrikefon provide pain relief that is not inferior to nalbuphine after ophthalmic surgery? * Does Anrikefon cause fewer central side effects, such as sedation or dizziness, compared with nalbuphine? * Does Anrikefon help patients recover and get discharged faster after day-surgery procedures? Researchers will compare Anrikefon to nalbuphine to see if Anrikefon can offer effective and safer perioperative analgesia for ophthalmic day-surgery patients.
Participants will:
* Receive either an intravenous dose of Anrikefon or nalbuphine during surgery. * Be monitored for pain scores, side effects, and recovery parameters after surgery. * Complete follow-up assessments.
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Phase 4
Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Anrikefon is a novel peripherally KOR agonist independently developed in China. In this study, anrikefon will be administered intravenously at a dose of 1 μg/kg, 15 minutes before the end of surgery.
Nalbuphine is a traditional central KOR agonist with mixed μ-opioid receptor antagonist activity. In this study, nalbuphine will be administered intravenously at a dose of 0.1 mg/kg, 15 minutes before the end of surgery.
Time frame: In the PACU and at 1 , 2 , 4 and 6 hours after surgery
Pain intensity at rest is recorded with the Numeric Rating Scale (NRS: 0 = no pain, 10 = worst possible pain). The area under the curve (AUC) for these scores will be calculated with the trapezoidal rule, using assessments performed in the PACU and at 1 , 2 , 4 and 6 hours post-operatively. A higher AUC indicates greater cumulative pain over the 6-hour period.
Time frame: In the PACU and at 1, 2, 4, 6, 12 and 24 hours, as well as 1 week and 1 month postoperatively
Participants rate their pain intensity at rest and again during voluntary eye movement using the Numeric Rating Scale (NRS: 0 = no pain, 10 = worst possible pain). Assessments are performed in the PACU and at 1, 2, 4, 6, 12, 24 hours, 1 week, and 1 month post-operatively. Higher scores indicate greater pain.
Time frame: In the PACU and at 1, 2, 4, 6, 12, and 24 hours postoperatively
The area under the curve (AUC) is computed with the trapezoidal rule, multiplying the average Numeric Rating Scale within each interval by its duration and summing the products; a higher AUC indicates greater cumulative pain.
Time frame: At 6, 12, and 24 hours postoperatively
In-hospital, participants with resting NRS ≥4 will receive intravenous flurbiprofen axetil 1 mg/kg. Additional doses can be given if ≥3 hours have passed since the previous flurbiprofen dose and ≥1 hour since the last study drug. Breakthrough pain (NRS ≥7) may be treated immediately. Out-of-hospital, participants with resting NRS ≥4 will receive paracetamol 500 mg per dose, up to 2 g per day.
Time frame: At 6, 12, and 24 hours postoperatively
During the 6-, 12-, and 24-hour postoperative periods, each patient's use of rescue analgesics (flurbiprofen axetil or paracetamol) is recorded. Patients not receiving rescue analgesics are classified as 'not used,' and the percentage is calculated for each group to evaluate postoperative analgesia adequacy.
Time frame: Within 24 hours postoperatively
A trained study assistant assessed satisfaction score of analgesia at rest using a 0 to 10 NRS scale, where 0 indicates 'completely dissatisfied' and 10 indicates 'completely satisfied.'
Time frame: Through surgery completion, an average of 1 hour.
Emergence time is defined as the interval from stopping anesthetics to eye opening or following simple commands.
Time frame: Through surgery completion, an average of 2 hours.
PACU stay time is defined as the duration from arrival in PACU to the time of a modified Aldrete score of 9 or 10.
Time frame: Through surgery completion, an average of 24 hours.
Time to first ambulation is defined as the interval from the completion of surgery to the patient's first episode of spontaneous mobilization (i.e., getting out of bed and initiating independent movement).
Time frame: Through surgery completion, an average of 24 hours
Postoperative hospital stay (or in-hospital stay for day-surgery patients) is defined as the interval from the completion of surgery to formal discharge from the hospital.
Time frame: In the PACU and within 24 hours postoperatively
All assessments of adverse events and medication records will be conducted under double-blind conditions, with evaluators blinded to participant group assignment. The incidence of adverse events will be calculated based on the total number of enrolled participants in each group.
Time frame: At 24 hours postoperatively
Postoperative recovery was assessed using the QoR-15 questionnaire.
Time frame: At 24 hours, 1 week, and 1 month postoperatively
Measured with non-contact tonometer; higher values indicate elevated IOP.
Time frame: At 24 hours, 1 week, and 1 month postoperatively
Graded by single examiner via digital palpation.
Time frame: At 24 hours, 1 week, and 1 month postoperatively
Assessed with standard LogMAR chart; lower LogMAR indicates better acuity.
Time frame: At 24 hours, 1 week, and 1 month postoperatively
Assessed with standard LogMAR chart after refraction; lower LogMAR indicates better acuity.
Time frame: At 2 and 24 hours postoperatively
Quantitative assessment around the periocular area of the operative eye using electronic Von Frey test.
Contact information is provided by the study sponsor or research team.
Xiaoliang Gan, PhD
CONTACT
Yanling Zhu, MD
CONTACT
Zhongshan Ophthalmic Center, Sun Yat-sen University
Other
Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic Surgery: A Multicenter, Randomized, Parallel-Control, Non-Inferiority Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07708740
Ketamine, Oculocardiac Reflex
Cairo, Egypt
View Trial DetailsNCT05901753
Ophthalmic Surgery
Cairo, Egypt
View Trial DetailsNCT00350363
Ophthalmic Surgery
Stanford, California, United States
View Trial DetailsNCT01258959
Ophthalmic Surgery, Parabulbar Block
Toronto, Ontario, Canada
View Trial Details